Drug intelligence / Profile preview

buspirone + levodopa + carbidopa

Development stage
Phase 2
Lead developer
Nordic Life Science Pipeline
Modality
Small Molecules
Administration
Oral
01

Overview

SPINALON (buspirone + levodopa + carbidopa) is a combination therapy being developed by Nordic Life Science Pipeline Inc. for the treatment of chronic spinal cord injury (SCI). It is designed as a Central Pattern Generator (CPG) activator to induce locomotor movements. The therapy combines buspirone, a 5-HT1A receptor agonist, with levodopa and carbidopa to increase spinal levels of serotonin and dopamine, respectively. These monoamine neurotransmitters are typically depleted below the level of injury in SCI patients, and their restoration is intended to increase the excitability of spinal motor neurons and interneurons, potentially enhancing the efficacy of epidural electrical stimulation (EES) and locomotor training.

Brand names
SPINALON
Other names
buspirone + levodopa-carbidopalevodopa + carbidopa + buspirone
02

Targets

DDC (Aromatic L-amino acid decarboxylase)DRD2 (Dopamine D2 Receptor)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))DRD (Dopamine receptors)

Beyond the preview

Go deeper on buspirone + levodopa + carbidopa.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on buspirone + levodopa + carbidopa.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call